BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bapineuzumab: Completed Phase III enrollment

Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Product: Bapineuzumab ( AAB-001)
Business: Neurology
Molecular target: Beta amyloid

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >